Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate

With these results, Breyanzi has now demonstrated clinically meaningful benefit across the broadest array of B-cell malignancies of any CD19-directed CAR T cell therapy, underscoring the company’s leadership in advancing innovative therapies for many types of...

Pall Life Sciences is now part of Cytiva!

We’re thrilled to share the news — Cytiva and the Life Sciences business of Pall have united under the Cytiva name! With a mission to advance therapeutics from discovery to delivery, combining our organizations just makes sense. Together, we bring broad and deep...